Beta-adrenoceptor blocking agents induce different counter-regulatory responses to insulin

Area of Science:

• Pharmacology
• Endocrinology
• Cardiovascular Medicine

Background:

• Concurrent use of antidiabetic drugs and beta-adrenoceptor blocking agents is common due to high rates of diabetes and cardiovascular disease.
• Understanding drug interactions is crucial for safe and effective patient management.

Purpose of the Study:

• To investigate the effects of specific beta-blockers (pindolol, metoprolol, propranolol) on the body's response to hypoglycemia and glucose challenges.
• To compare the impact of different beta-blockers on key metabolic and hormonal counterregulatory mechanisms.

Main Methods:

• Oral administration of pindolol, metoprolol, and propranolol to study participants.
• Assessment of responses to insulin-induced hypoglycemia and an oral glucose load.
• Monitoring of insulin clearance, glucose nadirs, and counterregulatory hormone secretion (epinephrine, growth hormone, ACTH, cortisol).

Main Results:

• Metoprolol and propranolol significantly inhibited insulin clearance and delayed glucose nadirs during hypoglycemia (p < 0.01).
• These agents also increased epinephrine, growth hormone, ACTH, and cortisol responses to hypoglycemia.
• Pindolol did not exhibit these inhibitory effects on insulin clearance or glucose recovery.
• Hypoglycemic symptoms included sweating and altered skin conductivity, with palpitations absent during beta-blockade; asymptomatic hypoglycemia was not observed.

Conclusions:

• Metoprolol and propranolol interfere with glucose counterregulation during hypoglycemia, potentially impacting diabetes management in patients with cardiovascular disease.
• Pindolol appears to have a different metabolic profile compared to metoprolol and propranolol regarding hypoglycemia.
• Clinical vigilance is necessary when prescribing these beta-blockers concurrently with antidiabetic medications.